Literature DB >> 9309267

Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens.

M P Oliveira-Neto1, A Schubach, M Mattos, S C Gonçalves-Costa, C Pirmez.   

Abstract

Twenty-three patients from Rio de Janeiro, Brazil-an area of Leishmania (Viannia) braziliensis transmission-were randomly assigned to receive either a high dose (20 mg/kg/day) of antimony or a lower one (5 mg/kg/day) in a 30 days series. The two treatment regimens showed similar responses. In 10 out of 12 patients receiving a dose of 5 mg/kg/day and 9 out of 11 patients with a dosage of 20 mg/kg/day a complete epithelization was noted by the end of treatment. In addition patients were followed for up to 7 years. No reactivation or development of mucosal lesions were observed in both groups during the extensive follow-up. We think that a low dosage of antimony could be equally effective than a higher one, at least in the presence of the clinical picture usually seen in Rio de Janeiro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9309267

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  9 in total

1.  In vitro sensitivity of paired Leishmania (Viannia) braziliensis samples isolated before meglumine antimoniate treatment and after treatment failure or reactivation of cutaneous leishmaniasis.

Authors:  Cibele Baptista; Luciana de Freitas Campos Miranda; Maria de Fátima Madeira; Leonor Laura Pinto Leon; Fátima Conceição-Silva; Armando de Oliveira Schubach
Journal:  Dis Markers       Date:  2015-01-31       Impact factor: 3.434

2.  Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.

Authors:  Caspar J Hodiamont; Piet A Kager; Aldert Bart; Henry J C de Vries; Pieter P A M van Thiel; Tjalling Leenstra; Peter J de Vries; Michèle van Vugt; Martin P Grobusch; Tom van Gool
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

3.  Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil.

Authors:  Mauricio Naoto Saheki; Marcelo Rosandiski Lyra; Sandro Javier Bedoya-Pacheco; Liliane de Fátima Antônio; Maria Inês Fernandes Pimentel; Mariza de Matos Salgueiro; Érica de Camargo Ferreira E Vasconcellos; Sonia Regina Lambert Passos; Ginelza Peres Lima Dos Santos; Madelon Novato Ribeiro; Aline Fagundes; Maria de Fátima Madeira; Eliame Mouta-Confort; Mauro Célio de Almeida Marzochi; Cláudia Maria Valete-Rosalino; Armando de Oliveira Schubach
Journal:  PLoS One       Date:  2017-05-30       Impact factor: 3.240

Review 4.  Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.

Authors:  Ludovic Reveiz; Ana Nilce Silveira Maia-Elkhoury; Rubén Santiago Nicholls; Gustavo Adolfo Sierra Romero; Zaida E Yadon
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

5.  Interventions for American cutaneous and mucocutaneous leishmaniasis.

Authors:  Mariona Pinart; José-Ramón Rueda; Gustavo As Romero; Carlos Eduardo Pinzón-Flórez; Karime Osorio-Arango; Ana Nilce Silveira Maia-Elkhoury; Ludovic Reveiz; Vanessa M Elias; John A Tweed
Journal:  Cochrane Database Syst Rev       Date:  2020-08-27

6.  Montenegro skin test and age of skin lesion as predictors of treatment failure in cutaneous leishmaniasis.

Authors:  Liliane de Fátima Antonio; Aline Fagundes; Raquel Vasconcellos Carvalhaes Oliveira; Priscila Garcia Pinto; Sandro Javier Bedoya-Pacheco; Erica de Camargo Ferreira e Vasconcellos; Maria Cláudia Valete-Rosalino; Marcelo Rosandiski Lyra; Sônia Regina Lambert Passos; Maria Inês Fernandes Pimentel; Armando de Oliveira Schubach
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Sep-Oct       Impact factor: 1.846

7.  Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.

Authors:  Madelon Novato Ribeiro; Maria Inês Fernandes Pimentel; Armando de Oliveira Schubach; Raquel de Vasconcellos Carvalhães de Oliveira; José Liporage Teixeira; Madson Pedro da Silva Leite; Monique Fonseca; Ginelza Peres Lima dos Santos; Mariza Matos Salgueiro; Erica de Camargo Ferreira e Vasconcellos; Marcelo Rosandiski Lyra; Mauricio Naoto Saheki; Claudia Maria Valete-Rosalino
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Jul-Aug       Impact factor: 1.846

8.  PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS.

Authors:  Marcelo Rosandiski Lyra; Sonia Regina Lambert Passos; Maria Inês Fernandes Pimentel; Sandro Javier Bedoya-Pacheco; Cláudia Maria Valete-Rosalino; Erica Camargo Ferreira Vasconcellos; Liliane Fatima Antonio; Mauricio Naoto Saheki; Mariza Mattos Salgueiro; Ginelza Peres Lima Santos; Madelon Noato Ribeiro; Fatima Conceição-Silva; Maria Fatima Madeira; Jorge Luiz Nunes Silva; Aline Fagundes; Armando Oliveria Schubach
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-09-22       Impact factor: 1.846

9.  Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013).

Authors:  Lucia Regina Brahim; Cláudia Maria Valete-Rosalino; Liliane de Fátima Antônio; Maria Inês Fernandes Pimentel; Marcelo Rosandiski Lyra; Luiz Eduardo de Carvalho Paes; Ananda Dutra da Costa; Iracema Forni Vieira; Cristina Maria Giordano Dias; Maria Cristina de Oliveira Duque; Mauro Celio de Almeida Marzochi; Armando de Oliveira Schubach
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-12       Impact factor: 2.743

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.